»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Dasatinib Monohydrate CAS 863127-77-9 Dasatinib hydrate manufacturer

5th

Gold Index: 89140

You are here: home  > New products  > Dasatinib Monohydrate CAS 863127-77-9 Dasatinib hydrate

Dasatinib Monohydrate CAS 863127-77-9 Dasatinib hydrate 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOS 29
Production Capacity: 3 Ton/Year
Delivery Date: within 7 days
Name: Dasatinib Monohydrate
Molecular Formula: C22H28ClN7O3S
Appearance: white powder
Storage condition: Dasatinib hydrate
Alias: MK-0869
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand: MOSINTER
CAS: 863127-77-9
Molecular Weight: 506.02082
Melting Point: Anti-cancer apis intermedia...
Use: Vomiting chemotherapy drug ...

Dasatinib Monohydrate CAS 863127-77-9 used to have treatment the people of drug resistance or chronic myelogenous leukemia can't tolerate all disease

Dasatinib Monohydrate CAS 863127-77-9 used to have treatment the people of drug resistance or chronic myelogenous leukemia can't tolerate all disease duration.


white powder


Dasatinib Monohydrate

Synonyms: dasatinib monohydrate;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;Dasatinib(TINIBS);N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate;Dastinib;Bms 35482503;Dasatinib hydrate

25KG drum


Dasatinib is a tyrosine kinase inhibitors, the main is based on four international from total included 911 patients, multicenter phase Ⅱ test the safety and efficacy of results and other supporting data and approved for use in the above two indications. It is the most commonly reported side effects in clinical research have fluid retention, gastrointestinal symptoms and bleeding events, etc.; The most frequently reported serious side effects is calorific, pleural effusion, febrile neutral white) used in myeloid leukemia.

package: 25KG Drum or According to the request of customer


Dasatinib is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients withchronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.


In a Phase I dose escalation study published in June 2006, dasatinib was tested in patients who were resistant to or who could not tolerateimatinib. Complete hematological responses were seen in 37 of 40 patients with chronic-phase CML. Major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML in blast crisis, or Ph+ ALL.


Responses were maintained in 95% of patients with chronic-phase CML, with a median follow-up time of >12 months. In patients with accelerated-phase CML, 82% remained in remission, although with a median follow-up of only 5 months. Nearly all patients with CML in blast crisis or Ph+ ALL relapsed within 6 months.


Neutropenia and myelosuppression were common toxic effects. Fifteen patients (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which were felt to be a side effect of dasatinib. Some of these patients required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of patients developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in patients treated with dasatinib.

On October 11, 2011 the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting dasatinib, including after more than one year of treatment.

Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.



bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: